US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) Elrexfio (elranatamab). The drug is now approved to treat triple-class exposed (TCE) relapsed or refractory multiple myeloma (r/r MM).
Mechanism of Action
Elrexfio works by binding to CD3 on T cells, directing these lymphocytes toward BCMA expressed on multiple myeloma (MM) cells. This innovative mechanism enhances the body’s immune response to target and eliminate cancer cells.
Global Approval Timeline
In August 2023, the US Food and Drug Administration (FDA) granted accelerated approval to Elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy. This fast-tracked approval highlights the drug’s potential to address significant unmet needs in oncology.-Fineline Info & Tech
Leave a Reply